Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Plate Based Real-Time Annexin V Method for Monitoring Antibody Drug Conjugate Induced Apoptosis and Cell Death

Part # PS314

Abstract

Steven Edenson1, Kevin Kupcho1, Andrew Niles1, John Shultz1, Jamison Grailer1, Wenhui Zhou2, Robin Hurst1, Jim Hartnett1, Terry Riss1, Dan Lazar1, and James Cali1
1Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711
2Promega Biosciences LLC, 277 Granada Drive, San Luis Obispo, CA 93401

Antibody drug conjugates (ADC) induce cell death via cognate interactions with surface antigens, internalization, release of toxin, and the binding of the toxin to its cellular targets. The key factors that determine the effectiveness of an ADC include the antibody, linker, toxin, and conjugation method. Testing all possible combinations can be challenging with assays that simply readout a single time point. To address this need, we developed a real-time, live cell assay method that utilizes a fully homogeneous, bioluminescent annexin V reagent. The method does not require laborious washing and sample preparation steps associated with traditional annexin methods and is fully compatible with plate-based multimodal signal detection systems. This work describes our efforts to characterize and compare the performance of the bioluminescent annexin assay to traditional endpoint assays after ADC exposure with target cells.

Printed in USA.